Literature DB >> 31236602

The increased T helper cells proliferation and inflammatory responses in patients with type 2 diabetes mellitus is suppressed by sitagliptin and vitamin D3 in vitro.

Elham Mahabadi-Ashtiyani1, Vida Sheikh2, Shiva Borzouei2, Iraj Salehi3, Mahdi Alahgholi-Hajibehzad4.   

Abstract

OBJECTIVE: The probably effects of sitagliptin and vitamin D3 (VitD3) on proliferation capacity and cytokines production were investigated in type 2 diabetes mellitus (T2DM) in vitro.
MATERIALS AND METHODS: Peripheral blood mononuclear cells (PBMCs) were isolated from 35 patients with T2DM and 26 healthy controls (HCs). CFSE-labeled PBMCs stimulated with phytohamagglutinin (PHA, 5 μg/mL) in the presence/absence of sitagliptin (200 mg/mL) with/without VitD3 (10-8 M) for 4 days. The proliferation of CD4+ T helper cells and non-CD4+ cells was analyzed using flow cytometry. The supernatant levels of IFN-γ, IL-17, IL-4, TGB-β and IL-37 were detected using ELISA.
RESULTS: The proliferation of CD4+ T cells in response to PHA was higher in T2DM patients compared with HCs. The production of IFN-γ and IL-17 in PHA-stimulated cultures was higher, and the levels of IL-4 and IL-37 were lower in T2DM patients compared to HCs. The addition of sitagliptin or VitD3 to the cultures decreased the CD4+ T cells and non-CD4+ cells proliferation in patients and HCs. Sitagliptin with VitD3 was more effective in suppression of proliferation, decreasing of IL-17 and enhancing of IL-37 production.
CONCLUSION: Sitagliptin plus VitD3 effectively reduces the proliferative T cells response and modulates pro-inflammatory/anti-inflammatory cytokines production.

Entities:  

Keywords:  Cytokine; Proliferation; Sitagliptin; T cell; T2DM; Vitamin D3

Mesh:

Substances:

Year:  2019        PMID: 31236602     DOI: 10.1007/s00011-019-01265-5

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  38 in total

1.  Reference ranges of lymphocyte subsets in healthy adults and adolescents with special mention of T cell maturation subsets in adults of South Florida.

Authors:  Ranjini Valiathan; Khaled Deeb; Marc Diamante; Margarita Ashman; Naresh Sachdeva; Deshratn Asthana
Journal:  Immunobiology       Date:  2014-03-02       Impact factor: 3.144

2.  1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4.

Authors:  M T Cantorna; W D Woodward; C E Hayes; H F DeLuca
Journal:  J Immunol       Date:  1998-06-01       Impact factor: 5.422

3.  IL-37 protects against obesity-induced inflammation and insulin resistance.

Authors:  Dov B Ballak; Janna A van Diepen; Alexander R Moschen; Henry J Jansen; Anneke Hijmans; Gert-Jan Groenhof; Floris Leenders; Philip Bufler; Mark V Boekschoten; Michael Müller; Sander Kersten; Suzhao Li; SooHyun Kim; Hadar Eini; Eli C Lewis; Leo A B Joosten; Herbert Tilg; Mihai G Netea; Cees J Tack; Charles A Dinarello; Rinke Stienstra
Journal:  Nat Commun       Date:  2014-09-03       Impact factor: 14.919

4.  Effects of sitagliptin and vitamin D3 on T helper cell transcription factors and cytokine production in clinical subgroups of type 2 diabetes mellitus: highlights upregulation of FOXP3 and IL-37.

Authors:  Zahra Telikani; Vida Sheikh; Alireza Zamani; Shiva Borzouei; Iraj Salehi; Mohammad Ali Amirzargar; Mahdi Alahgholi-Hajibehzad
Journal:  Immunopharmacol Immunotoxicol       Date:  2019-03-25       Impact factor: 2.730

5.  Modulation of immune cells and Th1/Th2 cytokines in insulin-treated type 2 diabetes mellitus.

Authors:  Magloire Pandoua Nekoua; Rufine Fachinan; Amidou K Atchamou; Odilon Nouatin; Daniel Amoussou-Guenou; Marcellin K Amoussou-Guenou; Kabirou Moutairou; Akadiri Yessoufou
Journal:  Afr Health Sci       Date:  2016-09       Impact factor: 0.927

Review 6.  Immunobiology of IL-37: mechanism of action and clinical perspectives.

Authors:  Shannon Quirk; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-10-18       Impact factor: 4.473

7.  A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.

Authors:  Noriko Satoh-Asahara; Yousuke Sasaki; Hiromichi Wada; Mayu Tochiya; Azusa Iguchi; Reiko Nakagawachi; Shinji Odori; Shigeo Kono; Koji Hasegawa; Akira Shimatsu
Journal:  Metabolism       Date:  2012-10-11       Impact factor: 8.694

8.  Type 2 diabetes impairs insulin receptor substrate-2-mediated phosphatidylinositol 3-kinase activity in primary macrophages to induce a state of cytokine resistance to IL-4 in association with overexpression of suppressor of cytokine signaling-3.

Authors:  Jason C O'Connor; Christina L Sherry; Christopher B Guest; Gregory G Freund
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

9.  The effect of interleukin (IL)-21 and CD4+ CD25++ T cells on cytokine production of CD4+ responder T cells in patients with myasthenia gravis.

Authors:  M Alahgholi-Hajibehzad; H Durmuş; F Aysal; Y Gülşen-Parman; P Oflazer; F Deymeer; G Saruhan-Direskeneli
Journal:  Clin Exp Immunol       Date:  2017-07-28       Impact factor: 4.330

Review 10.  Changes of Regulatory T Cells and of Proinflammatory and Immunosuppressive Cytokines in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.

Authors:  Yong-Chao Qiao; Jian Shen; Lan He; Xue-Zhi Hong; Fang Tian; Yan-Hong Pan; Ling Liang; Xiao-Xi Zhang; Hai-Lu Zhao
Journal:  J Diabetes Res       Date:  2016-09-29       Impact factor: 4.011

View more
  1 in total

1.  Nitazoxanide Exerts Immunomodulatory Effects on Peripheral Blood Mononuclear Cells from Type 2 Diabetes Patients.

Authors:  Mauricio Castillo-Salazar; Fausto Sánchez-Muñoz; Rashidi Springall Del Villar; Gabriel Navarrete-Vázquez; Adrián Hernández-DiazCouder; Carlos Mojica-Cardoso; Sara García-Jiménez; Cairo Toledano-Jaimes; Germán Bernal-Fernández
Journal:  Biomolecules       Date:  2021-12-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.